Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Todos Medical Ltd. (TOMDF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0178+0.0001 (+0.68%)
At close: 03:58PM EDT
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    Todos Medical Enters Into $50M Contract to Supply Tollovid™ and CBD Products to Retail Distributor Company Nerd Hemp

    5500 Automated Retail Machines to be Rolled out in Q4/22 and Q1/23 $11.5M in Q4/22 Revenue Expected From This Agreement NEW YORK, NY and TEL AVIV, ISRAEL, Sept. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that it has entered into a distributor agreement to supply its proprietary 3CL protease inhibitor immune support dietary supplement Tollovid™ and botanical ‘0% THC’ CBD pro

  • GlobeNewswire

    Todos Medical Announces NFL Hall of Famer Michael Irvin as Tollovid™ Sports Ambassador for #TolloUp Campaign

    NEW YORK, NY and Tel Aviv, ISRAEL, Sept. 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that Michael Irvin has agreed to become the Sports Ambassador for the Company’s 3CL Pharma’s majority-owned subsidiary’s #TolloUp marketing campaign for 3CL protease inhibitor immune support supplement Tollovid™. A recent market research study showed that 90%+ of both acute infection and Lon

  • GlobeNewswire

    Todos Medical Announces Preprint of Long COVID Case Study Participant with Confirmed Microclot and Hyperactivated Platelets who Benefitted from Tollovid

    New York, NY, and Tel Aviv, ISRAEL, Sept. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned joint venture 3CL Pharma Ltd. reported the preprint in ResearchGate of a case study entitled “Consequences of Microclot Pathophysiology Underlying Long COVID Improved with Tollovid Supplementation”, overseen by Dr. Lee Morgentaler and Andrew A. Blumenthal, RN ADS of

Advertisement
Advertisement